Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia

Cancer. 2005 Jan 1;103(1):210-11. doi: 10.1002/cncr.20742.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Dose-Response Relationship, Drug
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Hematopoietic Stem Cells
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Neutropenia / chemically induced*
  • Neutropenia / prevention & control*
  • Piperazines / adverse effects*
  • Piperazines / therapeutic use
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use
  • Reproducibility of Results

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Granulocyte Colony-Stimulating Factor
  • Imatinib Mesylate